Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults with type 1 diabetes, has not been well-evaluated in those with type 2 diabetes receiving insulin. Objective: To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin. Design: Randomized clinical trial. (The protocol also included a type 1 diabetes cohort in a parallel trial and subsequent second trial.) (ClinicalTrials.gov: NCT02282397). Setting: 25 endocrinology practices in North America. Patients: 158 adults who had had type 2 diabetes for a median of 17 years (interquartile range, 11 to 23 years). Participants were aged 35 to 79 years (mean, 60 years [SD, 10]), were receiving multiple daily injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5%). Intervention: Random assignment to CGM (n = 79) or usual care (control group, n = 79). Measurements: The primary outcome was HbA1c reduction at 24 weeks. Results: Mean HbA1c levels decreased to 7.7% in the CGM group and 8.0% in the control group at 24 weeks (adjusted difference in mean change, -0.3% [95% CI, -0.5% to 0.0%]; P = 0.022). The groups did not differ meaningfully in CGM-measured hypoglycemia or quality-of-life outcomes. The CGM group averaged 6.7 days (SD, 0.9) of CGM use per week. Limitation: 6-month follow-up. Conclusion: A high percentage of adults who received multiple daily insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had improved glycemic control. Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support an additional management method that may benefit these patients. Primary Funding Source: Dexcom.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefits of CGM in this population include reductions in A1C, fewer severe hypoglycemia events in children and adults, increased TIR, as well as significant reductions in hospitalizations for severe hypoglycemia and DKA.156,162–168”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“The clinical efficacy of CGM has been demonstrated in numerous retrospective studies and RCTs of individuals with T1D regardless of insulin delivery method.156–161”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“In addition, CGM use has been reported to reduce fear of hypoglycemia and increase confidence in avoiding/treating hypoglycemia.156,174,175”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [4]
In the citing paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [4]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Assessing Psychosocial Distress in Diabetes
Polonsky, W. H., Fisher, L., Earles, J., Dudl, R. J., Lees, J., Mullan, J., & Jackson, R. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.626 · Cited by 1,575
Self-citationContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 3×
“org), was identical to that of a parallel trial in patients with type 1 diabetes (12), which also had a second phase assessing insulin pump initiation.”
BackgroundResultSelf-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Cited by
Items 601–636 of 636
Liu, B., Hannah, K. L., Nemlekar, P. M., Green, C. R., & Norman, G. J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s574769
Banaś, A., Bigajski, H., Janczarski, S., Kwolek, K., Laskowska, W., Michalik, M., Owczarska, A., Pilarek, M., Sarna, D., & Widera, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4457
Toward terminological clarity in digital biomarker research
Mangalam, M., & Kiyono, K. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1796008 · Cited by 1
Lim, W., Zhong, Y., Bruno, J., Alemán, J. O., & Barua, S. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261427499
Watada, H., Tanaka, S., Matuoka, J. Y., Alshannaq, H. A., Pollock, R. F., Field, M., & Norman, G. J. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70279
Zhu, J., & Zhang, L. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02167-4
Willingness to adopt digital behavior change interventions in people with chronic conditions
Oikonomidi, T. (2021) · theses.fr (ABES) · doi:10.70675/1c55ba23zaa2az4f6ez987fz81d53ee22274
Blood glucose testing modalities utilized by people with type 2 diabetes in a secondary care setting
O’Farrell, R., Gardner, M., Davenport, C., Tun, T. K., Siddique, N., McDermott, J. H., & Sreenan, S. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-026-04347-6
Chico, A. I., Aguilera, E., Albareda, M., Moreno-Fernández, J., Beato-Víbora, P. I., Fernández-Rubio, E., Cuesta, M., Rodrigo, A. B., Ampudia‐Blasco, F. J., Bandrés, O., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02682-9 · Cited by 2
JENDLE, J. H., Adolfsson, P., Hellman, J., Klanger, B., & Ekberg, N. R. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261442987
Moderne Technologien: Nutzen auch für Menschen mit Typ-2-Diabetes?
Thomas, A., & Woitek, C. (2026) · Info Diabetologie · doi:10.1007/s15034-026-5248-y
Toward a Future Where Diabetes No Longer Limits Mesh Surgery
Liang, R. (2026) · International Urogynecology Journal · doi:10.1007/s00192-026-06675-8
Polonsky, W. H., Clark, T. L., Soriano, E. C., Edgington, A., Bennett, C. M., Fox, A. E., & Grace, T. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70236
Self-citationZhang, H., Li, J., Wang, D., Du, Q., & Zhang, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1830980 · Cited by 1
Diabetestechnologie (Update 2026)
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Hofer, S. E., Fröhlich-Reiterer, E. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Wascher, T. C., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02630-7
Khan, S. A., Singhal, P., Lathiya, T., Lodha, P., Joshi, A. S., Kapoor, D., Bansal, B., Mittal, S., Bhansali, A. K., Dogra, H., et al. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_191_25
Martens, T. W., Asche, S. E., JaKa, M. M., Johnson, M. L., DUNNIGAN, S. M., Haven, A. L., Morris, C., Barnaby, D., Maciosek, M. V., Dinh, J. M., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108357
Self-citationDzojic, K., Schönberger, E., Petrinović, M., Rimac, D. S., Erzic, E., Berković, M. C., Bakula, M., Bilić-Čurčić, I., & Canecki-Varžić, S. (2026) · Medicina · doi:10.3390/medicina62050938
Wearable systems for real-time disease diagnosis and predictive analytics
Huynh, P. K., Nguyen, D. H., Liu, H., Marahatta, S., Olaniran, O., Nguyen, D., Truong, T. T., Huynh, P., Keshwani, A., Prioli, J. P. J., et al. (2026) · Elsevier eBooks · doi:10.1016/b978-0-44-331426-1.00018-8
Manikandan, S., Shore, S., Waszczuk, D., Miriyala, S., & Sadanala, G. (2026) · Personalized Medicine · doi:10.1080/17410541.2026.2682847 · Cited by 1
Diabetes Technology: Continuous Glucose Monitoring and Insulin Delivery
MacLeod, J., Willis, H. J., Sulik, B., & Chomko, M. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch08 · Cited by 1
Rêgo, M. L. D. M., Barnett, M., de Melo, M. H. S. T., & Rivadeneira, A. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag150
Grady, M., MacKintosh, S., Fryett, M., & Holt, E. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101478
Hannah, K. L., Nemlekar, P. M., & Norman, G. J. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.26112
Sanchez, C. E., Ro, M., & Jones, R. (2026) · Patient Safety · doi:10.33940/001c.163571
Asgari, R., Mohammadi, N., Baradaran, H. R., Jabarbeigi, R., Osooli, M., & Jafari, E. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02057-5
Digital Health Technologies and Hypoglycaemia
Villard, O., & Renard, É. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_24
Glucose Monitoring: Advances in Technology
McDonnell, D. J., Smith, D., & Forde, H. E. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_4
Gómez, P. R. D. V., Díaz, Á. M. M., Sánchez, E. M., Gomez-Peralta, F., Umpierrez, G. E., & Brocca, M. A. M. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261492377
Knowledge and Attitudes Regarding Continuous Glucose Monitors as Predictors of Current Use
Gallegos, S. P., Zohn, J. H., Hutchins, A. M., Derksen, L. A., & Benton, M. J. (2026) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106261483745
Asghar, S., Shaikh, K., Nisar, A., Aftab, S., Qadeer, R., & Wahab, A. (2026) · Cureus · doi:10.7759/cureus.117117
Continuous Glucose Monitoring and Long-Term Glycemic and Kidney Outcomes
Karter, A. J., Parker, M. M., Finertie, H., Nugent, J. R., Gilliam, L. K., & Mahapatra, A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.37698
Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes
Oser, T. K., Martens, T. W., Ruedy, K. J., Bergford, S., Calhoun, P. M., Chang, K.-L., Kramer, E. S., Klug, B. A., Anderson, R. L., Cook, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2608571
Self-citation(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Tang, M., Nathan, D. M., Wexler, D. J., Putman, M. S., Higgins, J. M., Zheng, H., Rhee, E. P., de Boer, I. H., & Kalim, S. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109439
Czupryniak, L., Mysliwiec, M., Gellert, R., Jankowski, P., Mastalerz–Migas, A., Strojek, K., Walczak, M., & Targowski, T. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.10.010
Metadata
- Authors
- Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., Aronson, R., Toschi, E., Kollman, C., Bergenstal, R., & for the DIAMOND Study Group*
- Affiliations
- Joslin Diabetes Center (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-09-19
- Volume
- 167
- Issue
- 6
- Pages
- 365-374
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2753830550
- Semantic Scholar
- 4f35ac21c54271e1101cc587d928e543765ee06a
- Cited by
- 635
- References
- 31
- Citations by year
- 2026: 58 · 2025: 91 · 2024: 95 · 2023: 77 · 2022: 77 · 2021: 85 · 2020: 43 · 2019: 56 · 2018: 46 · 2017: 6
- FWCI
- 32.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, type 2 diabetes, multiple daily insulin injections, glycemic control, HbA1c reduction, hypoglycemia, quality of life, usual care, type 1 diabetes
- MeSH terms
- Adult, Aged, Bacterial Proteins, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Membrane Proteins, Middle Aged, Quality of Life, Blood Glucose Self-Monitoring, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.